首页> 外文OA文献 >FRI0292 TREATMENT RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IS ASSOCIATED WITH FAVORABLE CHANGES OF THE BODY COMPOSITION IN PATIENTS WITH ANKYLOSING SPONDYLITIS

【2h】

FRI0292 TREATMENT RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IS ASSOCIATED WITH FAVORABLE CHANGES OF THE BODY COMPOSITION IN PATIENTS WITH ANKYLOSING SPONDYLITIS

机译：Fri0292对生物疾病改性抗风湿药物的治疗反应与强直性脊柱炎患者身体组成的有利变化有关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
V. Rios Rodriguez; M. Protopopov; F. Proft; J. Rademacher; B. Muche; A. K. Weber; S. Lüders; H. Haibel; M. Verba; J. Sieper; D. Poddubnyy;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis [J] . Ishikawa Yuki, Hashimoto Motomu, Ito Hiromu, Seminars in Arthritis and Rheumatism . 2019,第2期

机译：抗核抗体发育与对类风湿性关节炎患者的生物疾病改性抗风湿药物的治疗反应不良有关
2. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial [J] . van der Heijde Desiree, Wei James Cheng-Chung, Dougados Maxime, The Lancet . 2018,第10163期

机译：Ixekizumab，一种白细胞介素-17A拮抗剂，治疗脊柱膜炎或射线摄影轴向脊椎动物，以前未经生物减少抗风湿药物（Coast-V）：16周的第3期随机，双盲，主动控制的结果和安慰剂对照试验
3. The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si [J] . Rotar Ziga, Tomsic Matija, Praprotnik Sonja Clinical rheumatology . 2019,第2期

机译：与其他肿瘤坏死因子-α抑制剂相比，Golimalab的持续性在日常临床实践中治疗类风湿性关节炎，强直性脊柱炎和银屑病性关节炎：从生物学疾病改性抗腹性药物治疗的术患者患者的观测结果 - biorx.si.
4. No adverse physiological responses to infrared whole body hyperthermia in patients with rheumatoid arthritis and ankylosing spondylitis compared to healthy subjects. [C] . F.G.J. OOSTERVELD, E. KOOPMAN, J. OLDE SCHOLTENHUIS, Advances in biomedical research . 2010

机译：与健康受试者相比，类风湿性关节炎和强直性脊柱炎患者对红外全身热疗没有不利的生理反应。
5. Exercise Partially Explains the Impact of Body Mass Index on Disease Activity in Ankylosing Spondylitis [D] . ?Liew, Jean W. 2020

机译：运动也部分解释了身体质量指数对疾病活动强直性脊柱炎的影响
6. Risk Factors Associated with Estimated Glomerular Filtration Rate in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis after Treatment with Biological Disease Modifying Anti-Rheumatic Drugs [O] . Sung Won Lee 2018

机译：类风湿关节炎和强直性脊柱炎患者接受生物疾病改良抗风湿药治疗后与估计的肾小球滤过率相关的危险因素
7. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial [O] . Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, 2018

机译：Ixekizumab，一种白细胞介素-17A拮抗剂，治疗脊柱膜炎或射线照相轴向脊椎炎，以前未经治疗生物疾病改性抗风湿药物（Coast-V）：16周的一期随机，双盲，活性 - 控制和安慰剂对照试验

FRI0292 TREATMENT RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IS ASSOCIATED WITH FAVORABLE CHANGES OF THE BODY COMPOSITION IN PATIENTS WITH ANKYLOSING SPONDYLITIS

著录项

引文网络

相似文献

相关主题

期刊订阅